image: Microscopic images showing leukemia cells treated with venetoclax alone (Ven), tedizolid alone (Ted), or both venetoclax and tedizolid for four days. This material relates to a paper that appeared in the Oct. 30, 2019, issue of Science Translational Medicine, published by AAAS. The paper, by D. Sharon at Princess Margaret Cancer Centre, Toronto in Toronto, ON, Canada; and colleagues was titled, "Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response." view more
Credit: D. Sharon <i>et al., Science Translational Medicine</i> (2019)